clinical trials, phase II as topic

Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial
Dmitriy Zamarin, Sven Walderich, Aliya Holland, Qin Zhou, Alexia E Iasonos, Jean M Torrisi, Taha Merghoub, Lewis F Chesebrough, Autumn S Mcdonnell, Jacqueline M Gallagher, Yanyun Li, Travis J Hollmann, Rachel N Grisham, Courtney L Erskine, Mathew S Block, Keith L Knutson, Roisin E O’Cearbhaill, Carol Aghajanian, Jason A Konner

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000829; DOI: 10.1136/jitc-2020-000829
Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma
Brendan Curti, Marka Crittenden, Steven K Seung, Christopher B Fountain, Roxanne Payne, ShuChing Chang, Jessica Fleser, Kimberly Phillips, Ian Malkasian, Lyn B Dobrunick, Walter J Urba

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000773; DOI: 10.1136/jitc-2020-000773
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
Jieqiong Liu, Qiang Liu, Ying Li, Qian Li, Fengxi Su, Herui Yao, Shicheng Su, Quanren Wang, Liang Jin, Ying Wang, Wan Yee Lau, Zefei Jiang, Erwei Song

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000696; DOI: 10.1136/jitc-2020-000696
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
Sandra P D'Angelo, Shailender Bhatia, Andrew S Brohl, Omid Hamid, Janice M Mehnert, Patrick Terheyden, Kent C Shih, Isaac Brownell, Celeste Lebbé, Karl D Lewis, Gerald P Linette, Michele Milella, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Marcis Bajars, Gülseren Güzel, Paul T Nghiem

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000674; DOI: 10.1136/jitc-2020-000674
Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
Lu Xie, Jie Xu, Xin Sun, Wei Guo, Jin Gu, Kuisheng Liu, Bingxin Zheng, Tingting Ren, Yi Huang, Xiaodong Tang, Taiqiang Yan, Rongli Yang, Kunkun Sun, Danhua Shen, Yuan Li

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000798; DOI: 10.1136/jitc-2020-000798
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
Michael Overman, Milind Javle, Richard E Davis, Pankaj Vats, Chandan Kumar-Sinha, Lianchun Xiao, Niharika B Mettu, Edwin R Parra, Al B Benson, Charles D Lopez, Veerendra Munugalavadla, Priti Patel, Lin Tao, Sattva Neelapu, Anirban Maitra

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000587; DOI: 10.1136/jitc-2020-000587

Log in using your username and password

Main menu

Log in using your username and password

You are here

clinical trials, phase II as topic